1. Home
  2. INCY vs LII Comparison

INCY vs LII Comparison

Compare INCY & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$117.60

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Logo Lennox International Inc.

LII

Lennox International Inc.

HOLD

Current Price

$542.25

Market Cap

17.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCY
LII
Founded
1991
1895
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
17.2B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
INCY
LII
Price
$117.60
$542.25
Analyst Decision
Buy
Hold
Analyst Count
21
13
Target Price
$103.52
$566.58
AVG Volume (30 Days)
1.7M
380.7K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
N/A
1.00%
EPS Growth
4173.33
1.11
EPS
1.47
3.35
Revenue
$3,394,635,000.00
$5,195,300,000.00
Revenue This Year
$10.44
$6.85
Revenue Next Year
$10.99
$5.76
P/E Ratio
$79.38
$166.44
Revenue Growth
13.67
N/A
52 Week Low
$67.17
$434.06
52 Week High
$118.97
$689.44

Technical Indicators

Market Signals
Indicator
INCY
LII
Relative Strength Index (RSI) 64.56 49.35
Support Level $98.50 $530.83
Resistance Level $118.97 $567.40
Average True Range (ATR) 3.02 16.97
MACD -0.25 -2.77
Stochastic Oscillator 78.21 22.88

Price Performance

Historical Comparison
INCY
LII

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About LII Lennox International Inc.

Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounts for 67% of sales and commercial HVAC (building climate solutions) accounts for the remaining 33% of sales. Lennox's commercial exposure is what its peers refer to as residential and light commercial, and lacks the scale and complexity of what is referred to as an applied solution. The company goes to market with multiple brands, but Lennox is its flagship HVAC brand.

Share on Social Networks: